Xcout Intel
AMICUS THERAPEUTICS INC
Amicus Therapeutics, Inc. is an American biopharmaceutical company focused on discovering and delivering advanced therapies for rare diseases. The company is publicly traded on Nasdaq and maintains its global corporate headquarters in Princeton, New Jersey.
Subscribe to see AMICUS THERAPEUTICS INC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
AMICUS THERAPEUTICS INC at a glance
AMICUS THERAPEUTICS INC is a biotech company headquartered in United States. It has raised at least $234.6M across the 3 funding rounds on record. Its most recent funding round raised $30M in October 2023. Xcout tracks 2 named people at AMICUS THERAPEUTICS INC, including Alexander Hardy (President and Chief Executive Officer).
AMICUS THERAPEUTICS INC leadership
- Alexander HardyPresident and Chief Executive Officer
- Jean-Jacques BienaiméChief Executive Officer
AMICUS THERAPEUTICS INC funding rounds
At least $234.6M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $30M | — | |
| SEC Form D filing | $199.9M | — | |
| SEC Form D filing | $4.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent AMICUS THERAPEUTICS INC news
AMICUS THERAPEUTICS INC competitors
A few of AMICUS THERAPEUTICS INC's closest competitors — see the full list of competitors and alternatives →
Amicus Therapeutics, a subsidiary of BioMarin Pharmaceutical Inc., is a biotechnology company that researches and delivers medicines for individuals living with genetically defined rare diseases. The company provides patient advocacy and support services alongside its clinical development pipeline.
Applied Therapeutics, Inc. is a biopharmaceutical company headquartered in New York City, focused on developing novel product candidates targeted at disease targets involving enzyme and metabolic pathways.
Travere Therapeutics is a biopharmaceutical company headquartered in San Diego, California, focused on identifying, developing, and delivering life-changing therapies for people living with rare diseases.
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Get AMICUS THERAPEUTICS INC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on AMICUS THERAPEUTICS INC in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access